Spending on hepatitis C treatments, including options from Gilead Sciences and AbbVie, increased 734 percent from 2013 to 2014.
Spending on specialty drugs, including treatments for conditions such as HCV, cancer and multiple sclerosis, accounted for 31 percent of drug spending last year, according to the report.
More articles on gastroenterology:
FDA advisory panel to discuss ‘superbug’ infections
3 MUSE procedures for GERD performed in Italy
Loyola University Health System adds Dr. Lesley Rhee
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
